Strategic approaches to enhance the adoption of GLP-1 analogs for diabetes and obesity treatment in India

The introduction of GLP-1 analogs in the Indian market holds great potential for diabetes and obesity management, yet their widespread adoption is hindered by several challenges. These include limited long-term data on cardiovascular and renal safety, high costs, lack of outpatient insurance coverage for major drugs, side effects, drug availability issues, and healthcare professionals' (HCPs) reluctance to prescribe them. In a country where many patients pay out-of-pocket and financial planning for healthcare is inadequate, these barriers are further amplified.
This study, involving a survey of 250 patients, explores the multifaceted landscape of GLP-1 analogs' acceptance in India. It examines dimensions such as financing schemes, market access strategies, internet trading, and the impact of biosimilars on pricing. By addressing gaps in discussions around discounts, rebates, profits, and price transparency, the research aims to identify key factors that could facilitate the early adoption of GLP-1 analogs in the Indian market.
The study advocates for a comprehensive strategy encompassing insurance coverage, patient-centric programs, effective branding, improved drug availability, increased public awareness, and the dissemination of long-term cardiovascular and renal safety data to HCPs. This holistic approach aims to enhance the accessibility of anti-diabetic and anti-obesity products in India, ultimately benefiting a large segment of the population struggling with these conditions. By fostering a deeper understanding and acceptance of GLP-1 among HCPs and patients, the study seeks to pave the way for the successful integration of these innovative therapies into the Indian healthcare system.